Abstract:The study investigated the clinical significance of RRM1 (ribonucleoside reductase subunit M1), TUBB3 (tubulin-β-III), TOP2A (DNA topoisomerase II), CYP19A1 (cytochrome P450, family 19, subfamily A, polypeptide 1) and CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) for the diagnosis and possible predictive roles in breast cancer. Tissue microarray detected the expression of RRM1, tubulin-β-III, Topo IIα, CYP19A1 and CYP2D6 protein in breast cancer tissue and tissue adjacent to tumors (TATs). In addition, a publically available tool, was used to assess the prognostic value of their gene expression in breast cancer (http://kmplot.com). Analysis for relapse-free survival (RFS), disease-free survival (DFS) and overall survival (OS) was performed. Cytoplasmic RRM1, tubulin-β-III, CYP19A1 and Topo IIα staining were significantly higher in breast cancer tissues compared with TATs (P<0.050). Significant correlation occurred between RRM1 expression with pathological classification (P=0.018), lymph node involvement (P=0.035) and ER status (P=0.003). Tubulin-β-III and CYP2D6 expression correlated significantly with tumor grade (P=0.021 for tubulin-β-III and P=0.029 for CYP2D6, respectively). Cox analysis showed that the protein expression of CYP2D6, CYP19A1, RRM1, Topo IIα or tubulin-β-III was not an independent prognostic factor. A significant association occurred between RFS and TUBB3, TOP2A, CYP19A1, and CYP2D6 mRNA expression. With CYP19A1 (P<0.001) and CYP2D6 (P<0.001), a high expression was associated with good clinical outcome. Conversely, a low expression of TUBB3 (P<0.001) and TOP2A (P<0.001) was associated with good clinical outcome. TUBB3 (P=0.0004) and TOP2A (P<0.001) were significant prognostic factors in predicting the patient OS. The expression of RRM1, tubulin-β-III, Topo IIα and CYP19A1 in tumor tissues was significantly higher than that in TATs. TUBB3, TOP2A, CYP19A1 and CYP2D6 gene expression, but not protein expression, was associated with patient survival.

[Expression and Clinical Significance of Cytokeratin 19 in Bone Marrow of Patients with Breast Cancer].

THE EXPRESSION AND CLINICAL SIGNIFICANCE OF CYTOKERATIN 20 mRNA IN CENTRAL VEIN BLOOD OF PATIENTS WITH GASTRIC CANCER BY RT-PCR

The Detection and Its Clinical Significance of Cytokeratin 19 Mrna (CK19 Mrna) in Pelvic Lymph Nodes of Cervical Cancer Patients

Clinical Significance of Cytokeratin 19 Mrna in the Peripheral Blood of Non-Small Cell Lung Cancer

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

Relationship between CK19 mRNA expression in peripheral blood cells and the clinical factors of breast cancer patients with axillary lymph node-negative

Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients.

Analysis of Sensitivity and Specificity of Cytokeratin 19 Reverse Transcriptase/polymerase Chain Reaction for Detection of Occult Breast Cancer in Bone Marrow and Leukapheresis Products.

Detection of Breast Cancer Micrometastases in Bone Marrow Using Reverse-Transcriptase Chain Reaction and Southern Hybridization

The Expression of Cytokeratin 19mrna and Its Clinical Significance in Bladder Carcinomas

Prognostic Value of Serum Cytokeratin19-2G2 in Primary Breast Cancer Patients.

Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19

Expression of Cytokeratin 19, 20 Mrna in Peripheral Venous Blood of Epithelial Malignancies Patients

Significance of cytokeratine detection for micrometastatic tumor cells in peripheral blood and bone marrow in patients with esophageal cancer

Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction.

Significance of Detecting Disseminated Tumor Cells in Peripheral Blood of Patients with Colorectal Carcinoma

Expression of CK19-mRNA in Cancerous and Paracancerous Tissues and Peripheral Blood of Lung Cancer Patients by Real-time Fluorescent Quantitative RT-PCR and Its Clinical Significance

Detection of Cytokeratin 19 Mrna in Peripheral Blood by RT-PCR in Patients with Renal Cell Carcinoma

Study of CK19 mRNA in blood of patients with colorectal cancer

Clinical Significance of CK20, CK19, CEA Mrnas in Peripheral Blood from Lung Cancer Patients

[Value of Diagnosing Micrometastasis by Nested RT-PCR in the Peripheral Blood and Bone Marrow in Non-Small Cell Lung Cancer Patients].